Dr. David R. Liljenquist, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
3910 Washington Parkway
Idaho Falls, ID 83404
Who else practices at this address →
Bonneville County includes primary care (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 844
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: George Washington University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
ID license M9285
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mountain View Hospital Idaho Falls, ID
- Portneuf Medical Center Pocatello, ID
- Eastern Idaho Regional Medical Center Idaho Falls, ID
- Madison Memorial Hospital Rexburg, ID
- Teton Valley Hospital Driggs, ID
Medical groups
- Rocky Mountain Diabetes and Osteoporosis Center PA (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 844
- Services billed
- 15,520
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, romosozumab-aqqg, 1 mg | 14,280 | 11 |
| Insertion of needle into vein for collection of blood sample | 963 | 682 |
| Injection, denosumab, 1 mg | 960 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 770 | 593 |
| Hemoglobin a1c level | 583 | 444 |
| Blood test, thyroid stimulating hormone (tsh) | 366 | 289 |
| Kidney function blood test panel | 318 | 280 |
| Blood test, lipids (cholesterol and triglycerides) | 310 | 287 |
| Parathormone (parathyroid hormone) level | 279 | 237 |
| Vitamin d-3 level | 223 | 208 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Idaho Falls, ID | 1,808 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Idaho Falls, ID | 1,407 |
| Atorvastatin Calcium Other prescribers in Idaho Falls, ID | 1,000 |
| Rosuvastatin Calcium Other prescribers in Idaho Falls, ID | 772 |
| Ozempic (semaglutide) Other prescribers in Idaho Falls, ID | 695 |
| Losartan Potassium Other prescribers in Idaho Falls, ID | 694 |
| Mounjaro (tirzepatide) Other prescribers in Idaho Falls, ID | 653 |
| Omeprazole Other prescribers in Idaho Falls, ID | 546 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Idaho Falls, ID | 524 |
| Pioglitazone Hcl Other prescribers in Idaho Falls, ID | 481 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 57 payments worth $1,126 in total to this clinician.
| Abbott Laboratories | $130 |
|---|---|
| Chiesi USA, Inc. | $105 |
| Madrigal Pharmaceuticals | $86.24 |
| Xeris Pharmaceuticals, Inc. | $78.40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $70.14 |
| Lilly USA, LLC | $61.04 |
| Corcept Therapeutics | $57.76 |
| Neurocrine Biosciences, Inc. | $51.07 |
| Food and Beverage | $1,060 |
|---|---|
| Education | $65.97 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Oct 27, 2025 | Education MYCAPSSA · ACROMEGALY | $65.97 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $1,557,391 in research payments for these studies, mostly to the institutions running them.
- Senseonics CTP0041
Senseonics, Incorporated - Senseonics CTP-0039
Senseonics, Incorporated - Innovative Automated Insulin Delivery System for Type 2 Diabetes
Sequel Med Tech, LLC · Completed · NCT06853990 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - Multi-session evaluation of the investigational dexcom continuous glucose monitoring (cgm) system in adult participants
Dexcom, Inc. - ISM2309001A--Janus 1
Abbott Laboratories - NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Abbott Laboratories - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - Senseonics CTP0039
Senseonics, Incorporated - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.